
AI in Research and Administration
TWINCORE establishes task force

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.
The LISA Summer School 2026 takes place from 23 August to 11 September 2026. Registration is open until 31 March.

TWINCORE establishes task force

TWINCORE scientist among 95 new Fellows of prestigious academy

OPERA research project launched to further develop antiviral active substances
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Schröter P, Steppich K, Fernández Carrera L, Song Z, Klein S, Souleiman R, Urbanek-Quaing M, Lietzau A, Schnieders A, Freyer E, Bremer B, León-Lara X, Almeida V, Gutierrez Jauregui R, Von Kaisenberg C, Bruhn M, Meineke C, Kalinke U, Wedemeyer H, Prinz I, Ravens S, Carpentier A, Bartsch Y, Kraft A, Cornberg M
Behrendt P, Neumann-Haefelin C
Prallet S, Maier N, Li A, Afting C, Huang H, Hu J, Toprak E, Keya D, Colasanti O, León-Janampa N, Marlet J, Beisel C, Mogler C, Puchas P, Behrendt P, Boettler T, Steinmann E, Saha S, Laketa V, Lohmann V, Wittbrodt J, Hermann C, Dill M, Dao Thi V
In collaboration with the Department of Neurology and the Metabolomics Department, the project is investigating metabolic products in cerebrospinal fluid in order to identify biomarkers for CNS infections and cell damage and to distinguish long COVID and viral from autoimmune diseases.
We are investigating how the association of HCV with lipoproteins contributes to the persistence of the virus by influencing entry into liver cells and protecting against antibodies. The aim is to gain new insights for the development of an HCV vaccine.
We are investigating how antibodies protect against HCV infection, in particular what properties they have during a healing infection. The aim is to identify antibodies that are important for an effective vaccine against HCV.
The CoViPa consortium uses computer-assisted high-throughput virus discovery and evolutionary analyses to identify RNA viruses with high spillover risk and potential animal host reservoirs and to investigate new pathogenicity factors.
"Challenge Orphan medicines – learnings from the past"
"Interaction with regulators, e.g. in preparation of a first clinical study"
"Why is knowledge in regulatory science important for translational medicine and basic science?"

